<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02579382</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-283-1062</org_study_id>
    <secondary_id>2015-002017-30</secondary_id>
    <nct_id>NCT02579382</nct_id>
  </id_info>
  <brief_title>A Study of the Safety, Tolerability, and Efficacy of Vesatolimod in Combination With Tenofovir Disoproxil Fumarate (TDF) in Adults With Chronic Hepatitis B (CHB) Infection Who Are Currently Not Being Treated</brief_title>
  <official_title>A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Safety and Efficacy of GS-9620 in Combination With Tenofovir Disoproxil Fumarate (TDF) for the Treatment of Subjects With Chronic Hepatitis B and Who Are Currently Not on Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of this study are to evaluate the safety, tolerability, and efficacy
      of vesatolimod (formerly GS-9620) in adults with chronic hepatitis B (CHB) infection who are
      currently not being treated.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 10, 2015</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Actual">January 16, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change (Measured in log10 IU/mL) in Serum Hepatitis B Surface Antigen (HBsAg) from Baseline at Week 24</measure>
    <time_frame>Baseline; Week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportions of Participants with Hepatitis B e Antigen (HBeAg) Loss and Seroconversion at Week 24</measure>
    <time_frame>Baseline; Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of Participants with Hepatitis B e Antigen (HBeAg) Loss and Seroconversion at Week 48</measure>
    <time_frame>Baseline; Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of Participants with HBsAg Loss and Seroconversion at Week 24</measure>
    <time_frame>Baseline; Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of Participants with HBsAg Loss and Seroconversion at Week 48</measure>
    <time_frame>Baseline; Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change (Measured in log10 IU/mL) in HBsAg from Baseline at Week 12</measure>
    <time_frame>Baseline; Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change (Measured in log10 IU/mL) in HBsAg from Baseline at Week 48</measure>
    <time_frame>Baseline; Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of Participants with a ≥ 0.5 log10 IU/mL Decline in Serum HBsAg Titers from Baseline at Week 12</measure>
    <time_frame>Baseline; Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of Participants with a ≥ 0.5 log10 IU/mL Decline in Serum HBsAg Titers from Baseline at Week 24</measure>
    <time_frame>Baseline; Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of Participants with a ≥ 0.5 log10 IU/mL Decline in Serum HBsAg Titers from Baseline at Week 48</measure>
    <time_frame>Baseline; Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of Participants with Hepatitis B Virus (HBV) DNA &lt; Lower Limit of Quantitation (LLOQ) at Week 24</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of Participants with Hepatitis B Virus (HBV) DNA &lt; Lower Limit of Quantitation (LLOQ) at Week 48</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Experiencing Virologic Breakthrough</measure>
    <time_frame>Up to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants with Drug Resistance Mutations</measure>
    <time_frame>Up to Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) Parameter: AUClast of Vesatolimod</measure>
    <time_frame>Predose, 0.5, 1, 2, 4, 6, 8, 10, 12, and 24 hours postdose</time_frame>
    <description>AUClast is defined as the concentration of drug from time zero to the last observable concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: AUCinf of Vesatolimod</measure>
    <time_frame>Predose, 0.5, 1, 2, 4, 6, 8, 10, 12, and 24 hours postdose</time_frame>
    <description>AUCinf is defined as the concentration of drug extrapolated to infinite time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: %AUCexp of Vesatolimod</measure>
    <time_frame>Predose, 0.5, 1, 2, 4, 6, 8, 10, 12, and 24 hours postdose</time_frame>
    <description>%AUCexp is defined as the percentage of AUC extrapolated between AUClast and AUCinf.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: Cmax of Vesatolimod</measure>
    <time_frame>Predose, 0.5, 1, 2, 4, 6, 8, 10, 12, and 24 hours postdose</time_frame>
    <description>Cmax is defined as the maximum concentration of drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: Clast of Vesatolimod</measure>
    <time_frame>Predose, 0.5, 1, 2, 4, 6, 8, 10, 12, and 24 hours postdose</time_frame>
    <description>Clast is defined as the last observable concentration of drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: Tmax of Vesatolimod</measure>
    <time_frame>Predose, 0.5, 1, 2, 4, 6, 8, 10, 12, and 24 hours postdose</time_frame>
    <description>Tmax is defined as the time (observed time point) of Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: Tlast of Vesatolimod</measure>
    <time_frame>Predose, 0.5, 1, 2, 4, 6, 8, 10, 12, and 24 hours postdose</time_frame>
    <description>Tlast is defined as the time (observed time point) of Clast.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: T1/2 of Vesatolimod</measure>
    <time_frame>Predose, 0.5, 1, 2, 4, 6, 8, 10, 12, and 24 hours postdose</time_frame>
    <description>T1/2 is defined as the estimate of the terminal elimination half-life of the drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: CL/F of Vesatolimod</measure>
    <time_frame>Predose, 0.5, 1, 2, 4, 6, 8, 10, 12, and 24 hours postdose</time_frame>
    <description>CL/F is defined as the apparent oral clearance following administration of the drug.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">192</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>TDF + placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>TDF + placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TDF + vesatolimod 1 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TDF + vesatolimod 1 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TDF + vesatolimod 2 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TDF + vesatolimod 2 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TDF + vesatolimod 4 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TDF + vesatolimod 4 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TDF</intervention_name>
    <description>300 mg tablets administered orally once daily</description>
    <arm_group_label>TDF + placebo</arm_group_label>
    <arm_group_label>TDF + vesatolimod 1 mg</arm_group_label>
    <arm_group_label>TDF + vesatolimod 2 mg</arm_group_label>
    <arm_group_label>TDF + vesatolimod 4 mg</arm_group_label>
    <other_name>Viread®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vesatolimod</intervention_name>
    <description>Tablets administered orally once a week (every 7 days) for 12 doses</description>
    <arm_group_label>TDF + vesatolimod 1 mg</arm_group_label>
    <arm_group_label>TDF + vesatolimod 2 mg</arm_group_label>
    <arm_group_label>TDF + vesatolimod 4 mg</arm_group_label>
    <other_name>GS-9620</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo administered orally once a week (every 7 days) for 12 doses</description>
    <arm_group_label>TDF + placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Adult males or females between the ages of 18-65

          -  Chronic HBV infection

          -  HBV DNA ≥ 2000 IU/mL at screening

        Key Exclusion Criteria:

          -  Extensive bridging fibrosis or cirrhosis

          -  Received oral antiviral treatment for HBV or prolonged therapy with immune-modulators
             or biologics within 3 months of screening

          -  Co-infection with hepatitis C virus (HCV), HIV or hepatitis D virus (HDV)

          -  Chronic liver disease other than HBV

          -  Lactating or pregnant females or those that wish to become pregnant during the course
             of the study

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Catonsville</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Flushing</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kowloon</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Giovanni Rotondo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Grafton</city>
        <state>Auckland</state>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dalin</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Hong Kong</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>New Zealand</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 15, 2015</study_first_submitted>
  <study_first_submitted_qc>October 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2015</study_first_posted>
  <disposition_first_submitted>December 4, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>December 4, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">December 7, 2017</disposition_first_posted>
  <last_update_submitted>February 9, 2018</last_update_submitted>
  <last_update_submitted_qc>February 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HBV</keyword>
  <keyword>Hepatitis</keyword>
  <keyword>Liver Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

